Emergent BioSolutions is a company that manufactures medical treatments, drug products, and vaccines. In 2021, Emergent BioSolutions entered into a partnership with Providence Therapeutics to develop a COVID-19 vaccine. The agreement and partnership were signed on a five-year contract for development and manufacturing services. Providence Therapeutics is an industry-leading vaccine manufacturer in Canada. The partnership's goal is to manufacture millions of PTX-COVID19-B drug products and batches of the PTX-COVID19-B formula drug for people throughout the world to resist the coronavirus.
The agreement and partnership are valued at over $90 million, which covers manufacturing processes and facility or equipment acquisitions. The vaccines will be manufactured in the Canada-based facilities of Emergent BioSolutions and will be distributed to developing countries that require protection. The vaccine will also be analyzed and further developed in the headquarters of the company in Maryland before it will be distributed throughout the world.